Search Results

ChromaCode, Inc. today announced a partnership with Department of Pathology, Medical College of Georgia , to test the analytical and clinical performance of ChromaCode’s HDPCR non-small cell lung cancer.

ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, announces Mark McDonough as Chair of the Board, the retirement of former Chair Carol Gallagher , Pharm.D., and the appointment of Michele Park, Ph.D. to the Board.

ChromaCode, Inc. today announced the signing of an early access agreement with Tennessee Oncology, a nationally recognized oncology practice with 35 clinical sites of care across Tennessee and in Northwest Georgia, to test the analytical and clinical performance of ChromaCode’s HDPCR non-small cell lung cancer (NSCLC) biomarker assay.

ChromaCode, Inc. today announced the publication of a study entitled " NSCLC Digital PCR Panel Returns Low Input Sample Results Where Sequencing Fails " in the journal Diagnostics.

ChromaCode, Inc. is proud to announce the publication of the first peer-reviewed demonstration of non-small-cell lung cancer (NSCLC) variant detection using ChromaCode’s groundbreaking High Definition PCR (HDPCR™) technology.

ChromaCode, Inc. will present new data during a Corporate workshop and present two accepted scientific abstracts at the Association for Molecular Pathology 2023 annual meeting, being held at the Salt Palace Convention Center in Salt Lake City, Utah, from November 14-18, 2023.

ChromaCode, Inc. announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing advanced cancer diagnostic technologies.

ChromaCode, a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, today announced a strategic investment from corporate venture capital fund Shimadzu Future Innovation Fund L.P., with general partner Global Brain Corporation.

ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to India and the Middle East.

ChromaCode, Inc. announced today that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization of ChromaCode’s HDPCR SARS-CoV-2 Assay to include several new qPCR instruments and use of 384-well plates.